MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company’s wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company’s products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
Market Dynamics | Explore MIMEDX's position in the $3.9 billion Advanced Wound Care and Surgical Markets, with projected growth in skin substitutes segment to $2.0 billion by 2026 |
Financial Resilience | Delve into MIMEDX's robust financial health, with 83.4% gross margin and 10.9% revenue growth, despite market challenges and regulatory headwinds |
Clinical Excellence | Learn about MIMEDX's product differentiation, supported by over 50 publications showcasing strong clinical results, including a 97% wound closure rate for DFUs |
Strategic Outlook | Discover MIMEDX's strategic initiatives, including new product launches and market expansion, with analyst targets around $11.00 per share |
Metrics to compare | MDXG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDXGPeersSector | |
---|---|---|---|---|
P/E Ratio | 24.6x | −5.3x | −0.5x | |
PEG Ratio | −0.65 | 0.00 | 0.00 | |
Price/Book | 4.9x | 1.8x | 2.6x | |
Price / LTM Sales | 2.8x | 9.3x | 3.1x | |
Upside (Analyst Target) | 77.0% | 209.8% | 46.1% | |
Fair Value Upside | Unlock | 32.9% | 6.9% | Unlock |